Bosh sahifaABCL • NASDAQ
add
AbCellera Biologics Inc
2,57 $
Seans yopilganidan keyin:(0,78%)+0,020
2,59 $
Yopilgan:25-apr, 20:00:00 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
2,60 $
Kunlik diapazon
2,54 $ - 2,64 $
Yillik diapazon
1,89 $ - 4,34 $
Bozor kapitalizatsiyasi
765,83 mln USD
Oʻrtacha hajm
4,00 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 5,05 mln | -44,98% |
Joriy xarajat | -271,00 ming | -101,02% |
Sof foyda | -34,21 mln | 27,44% |
Sof foyda marjasi | -677,43 | -31,88% |
Har bir ulushga tushum | -0,12 | 25,00% |
EBITDA | -26,04 mln | 55,50% |
Amaldagi soliq stavkasi | 26,95% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 625,61 mln | -17,75% |
Jami aktivlari | 1,36 mlrd | -8,57% |
Jami passivlari | 304,47 mln | -9,32% |
Umumiy kapital | 1,06 mlrd | — |
Tarqatilgan aksiyalar | 297,99 mln | — |
Narxi/balansdagi bahosi | 0,73 | — |
Aktivlardan daromad | -7,40% | — |
Kapitaldan daromad | -8,97% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -34,21 mln | 27,44% |
Operatsiyalardan naqd pul | -8,00 mln | 59,21% |
Sarmoyadan naqd pul | 35,70 mln | 246,79% |
Moliyadan naqd pul | 4,14 mln | 10,01% |
Naqd pulning sof oʻzgarishi | 29,68 mln | 175,92% |
Boʻsh pul | -72,44 mln | -28 861,47% |
Haqida
AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization that is contracted by biotechnology and pharmaceutical companies for antibody services, and researches and develops human antibodies as a service for its clients. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
CEO
Tashkil etilgan
2012
Sayt
Xodimlar soni
596
